Bruker Corporation (NASDAQ:BRKR) Receives $51.30 Average Target Price from Brokerages

Key Points

• Bruker Corporation (NASDAQ:BRKR) has received a consensus rating of "Hold" from analysts, with an average price target of $51.30.
• CEO Frank H. Laukien purchased 2,608 shares at approximately $38.36 each, increasing his stake in the company, which is currently valued at approximately $1.475 billion.
• The company recently reported quarterly earnings of $0.32 per share, missing estimates, along with a revenue decrease of 0.4% year-over-year.

Shares of Bruker Corporation (NASDAQ:BRKR - Get Free Report) have received an average rating of "Hold" from the eleven analysts that are covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $51.30.

A number of equities analysts have commented on BRKR shares. The Goldman Sachs Group cut their price objective on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th. Citigroup cut their price target on shares of Bruker from $40.00 to $38.00 and set a "neutral" rating for the company in a report on Monday, August 4th. UBS Group dropped their target price on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating for the company in a report on Thursday, May 8th. Jefferies Financial Group set a $60.00 price target on shares of Bruker and gave the stock a "buy" rating in a report on Monday, August 4th. Finally, Wells Fargo & Company decreased their target price on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 5th.

Insider Buying and Selling at Bruker

In other news, CEO Frank H. Laukien acquired 2,608 shares of the company's stock in a transaction that occurred on Friday, June 6th. The shares were purchased at an average price of $38.36 per share, for a total transaction of $100,042.88. Following the completion of the acquisition, the chief executive officer owned 38,462,171 shares of the company's stock, valued at approximately $1,475,408,879.56. This represents a 0.01% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 27.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Bruker

Large investors have recently added to or reduced their stakes in the stock. London Co. of Virginia boosted its position in shares of Bruker by 78.4% in the fourth quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company's stock valued at $245,820,000 after acquiring an additional 1,843,294 shares during the period. Sculptor Capital LP boosted its position in shares of Bruker by 51.6% in the first quarter. Sculptor Capital LP now owns 2,598,438 shares of the medical research company's stock valued at $108,459,000 after acquiring an additional 884,423 shares during the period. Brown Advisory Inc. boosted its position in shares of Bruker by 18.9% in the first quarter. Brown Advisory Inc. now owns 2,410,137 shares of the medical research company's stock valued at $100,599,000 after acquiring an additional 383,425 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Bruker by 22.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,687,364 shares of the medical research company's stock valued at $98,914,000 after acquiring an additional 313,171 shares during the period. Finally, Ameriprise Financial Inc. boosted its position in shares of Bruker by 10.6% in the fourth quarter. Ameriprise Financial Inc. now owns 1,615,358 shares of the medical research company's stock valued at $94,692,000 after acquiring an additional 154,768 shares during the period. Institutional investors own 79.52% of the company's stock.

Bruker Stock Performance

BRKR stock traded up $1.58 on Friday, hitting $32.36. The company's stock had a trading volume of 2,460,446 shares, compared to its average volume of 2,463,805. The firm has a 50 day moving average of $39.33 and a two-hundred day moving average of $42.24. Bruker has a 1 year low of $30.00 and a 1 year high of $72.94. The stock has a market cap of $4.91 billion, a price-to-earnings ratio of 62.23, a price-to-earnings-growth ratio of 2.52 and a beta of 1.16. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The firm had revenue of $797.40 million for the quarter, compared to analysts' expectations of $811.17 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%. The firm's quarterly revenue was down .4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS. Equities analysts predict that Bruker will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. Bruker's dividend payout ratio is 38.46%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.